% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Baertsch:124452,
      author       = {M.-A. Baertsch and J. Schlenzka and K. Lisenko and J.
                      Krzykalla$^*$ and N. Becker$^*$ and K. Weisel and R.
                      Noppeney and H. Martin and H. W. Lindemann and M. Haenel and
                      A. Nogai and C. Scheid and H. Salwender and R. Fenk and U.
                      Graeven and P. Reimer and M. Schmidt-Hieber and M. Goerner
                      and I. G. H. Schmidt-Wolf and S. Klein and A. D. Ho and H.
                      Goldschmidt and P. Wuchter},
      title        = {{C}yclophosphamide-based stem cell mobilization in relapsed
                      multiple myeloma patients: {A} subgroup analysis from the
                      phase {III} trial {R}e{LA}ps{E}.},
      journal      = {European journal of haematology},
      volume       = {99},
      number       = {1},
      issn         = {0902-4441},
      address      = {Oxford},
      publisher    = {Wiley-Blackwell},
      reportid     = {DKFZ-2017-01329},
      pages        = {42 - 50},
      year         = {2017},
      abstract     = {Analysis of the efficiency and toxicity of
                      cyclophosphamide-based stem cell mobilization in patients
                      with relapsed multiple myeloma (RMM).Peripheral blood stem
                      cells (PBSCs) were mobilized with high dose cyclophosphamide
                      (2 g/m(2) daily on days 1 and 2) and G-CSF plus
                      pre-emptive/rescue plerixafor in RMM patients (first to
                      third relapse) treated within the ReLApsE trial of the
                      German-Speaking Myeloma Multicenter Group
                      (GMMG).Mobilization was initiated with high-dose
                      cyclophosphamide (HD-CY) and G-CSF in 30 patients. Fifteen
                      patients received additional pre-emptive/rescue
                      administration of plerixafor. Stem cell collection was
                      successful (≥2×10(6) CD34+ cells per kg bw) in $77\%$
                      (23/30 patients). Patients with prior high-dose melphalan
                      collected a significantly lower median total number of PBSCs
                      than patients without prior high-dose melphalan (3.3×10(6)
                      vs 17×10(6) CD34+ cells/kg bw). Toxicity of HD-CY was
                      frequent with 12 serious adverse events (SAE) in $37\%$ of
                      patients (11/30 patients). Infections accounted for the
                      majority of SAE reports. In two patients, SAEs were lethal
                      (septic shock).These data proof feasibility of PBSC
                      collection at relapse but emphasize the importance of
                      collection and storage of additional PBSC transplants during
                      first-line treatment when mobilization is more efficient and
                      less toxic.},
      cin          = {C060},
      ddc          = {610},
      cid          = {I:(DE-He78)C060-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:28370401},
      doi          = {10.1111/ejh.12888},
      url          = {https://inrepo02.dkfz.de/record/124452},
}